Guest Editor(s)

• Prof. Francois-Xavier Claret

  Department of Systems Biology, Division of Basic Science Research, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

  Website | E-mail

• Prof. José Rueff

  Nova Medical School (NMS), Universidade Nova de Lisboa/Faculty of Medical Sciences, New University of Lisbon, Lisbon, Portugal.

  Website | E-mail

Special Issue Introduction

Non-coding RNAs (ncRNAs) have been identified to be key players in health and disease which are deregulated in cancer which can influence the development of resistance to treatment. This special issue summarizes recent advances on the impact of ncRNAs on therapy resistance in cancer and highlights how ncRNA expression profiles can predict clinical outcome in cancer. Finally, we will provide an overview of the challenges of ncRNA-targeted therapies for reversing drug resistance to sensitize tumor cells to chemotherapy, radiotherapy, and targeted treatment.

Keywords

miRNA, lncRNA, resistance, expression profile, Network, predictive biomarker, miR signature, tumorigenesis, therapy

Submission Deadline

30 Jun 2019

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://cdrjournal.com/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/CDR/?IssueId=264
Submission Deadline: 30 Jun 2019
Contacts: Elaine Gao, Managing Editor, editorial@cdrjournal.com
Chloe Yang, Assistant Editor, chloe@cdrjournal.com